Roche’s VENTANA CLDN18 (43-14A) RxDx Assay to Identify Patients with Gastric Or GEJ Cancer

Roche’s VENTANA CLDN18 (43-14A) RxDx Assay to Identify Patients with Gastric Or GEJ Cancer

By, Admin 14 October 2024

Roche’s IHC companion diagnostic test, VENTANA CLDN18 (43-14A) RxDx Assay to identify patients with gastric or GEJ cancer gets CE Mark approval

Overview

Roche announced that the VENTANA CLDN18 (43-14A) RxDx Assay is the first immunohistochemistry (IHC) companion diagnostic test to receive CE Mark approval for determining CLDN18 protein expression in tumours of patients with gastric or gastroesophageal junction (GEJ) adenocarcinoma. These patients now may be eligible for treatment with Astellas’ targeted therapy VYLOY (zolbetuximab).

Statement from the CEO: Roche Diagnostics

  • Gastric cancer remains a significant global health challenge. In Europe, only three percent of patients with metastatic disease live beyond five years,"" said Matt Sause, CEO of Roche Diagnostics. 
  • Our new companion diagnostic is a significant step forward for patients. By identifying those who may benefit from a targeted treatment, this new test can expand treatment possibilities, and aid clinicians to potentially improve outcomes.

Current Guidelines for Gastric Cancer

  • Current guidelines for gastric/GEJ cancer recommend using biomarkers to guide therapeutic decision making. 
  • The new VENTANA CLDN18 (43-14A) RxDx Assay can help determine CLDN18.2 status and inform clinicians about the likelihood of patients benefiting from CLDN18.2 targeted therapy. 
  •  VYLOY is the first approved treatment specifically targeting CLDN18.2-positive gastric/GEJ cancer, expanding options for patients to receive therapies appropriate for their specific disease.

About Gastric Cancer

  • Gastric cancer is the fifth most common cancer worldwide, with some of the highest rates observed in Central and Eastern Europe. 
  • The disease is often diagnosed late, because signs and symptoms are common to other conditions, resulting in an overall survival rate of just 25% among patients in the EU.

VENTANA CLDN18 RxDx Assay

  • The VENTANA CLDN18 (43-14A) RxDx Assay is a qualitative immunohistochemical assay intended to be used in the assessment of Claudin 18 (CLDN18) protein in gastric adenocarcinoma including gastroesophageal junction (GEJ) adenocarcinoma. 
  • The OptiView DAB IHC Detection Kit is used for staining on a BenchMark ULTRA instrument. 
  • The assay is indicated as an aid in identifying patients with gastric or GEJ adenocarcinoma who may be eligible for treatment with VYLOY (zolbetuximab) in accordance with the approved therapeutic product labelling. 
  • The Roche test measures expression of both variants of the CLDN18 protein (18.1 and 18.2 isoforms). CLDN18.2 is the predominant variant expressed in gastric and GEJ cancers.

Approval of the VENTANA CLDN18

  • The approval of the VENTANA CLDN18 (43-14A) RxDx Assay is based on the results of the SPOTLIGHT and GLOW clinical studies where it was used as the enrollment assay to identify patients whose tumours were CLDN18.2 positive. 
  • CLDN18.2 positivity is defined as = 75% of tumour cells demonstrating moderate to strong membrane CLDN18 staining as measured by the VENTANA CLDN18 (43-14A) RxDx Assay. 
  • In these studies, approximately 38% of gastric/GEJ cancer patients expressed high levels of CLDN18 and were considered CLDN18.2 positive by the VENTANA CLDN18 (43-14A) RxDx Assay. 
  • Patients who received a combination of zolbetuximab and chemotherapy experienced a 25-31% reduction in disease progression or death.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!